OCA was designed as a potent FXR agonist, it alleviates bile acids-induced hepatotoxicity (Trivedi et al., 2016) and NAFLD via FXR activation (Watanabe et al., 2004). This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.